Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 15||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Interferon alpha-2b||Intron A||Alfatronol|Alfatronol|interferon alpha-2b|Sch 30500|
|SV-BR-1-GM||Bria-IMT||SV-BR-1-GM is a vaccine comprised of breast cancer cells from the cell line, SV-BR-1, and granulocyte-macrophage colony-stimulating factor, which may lead to an immune response against breast cancer cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03066947||Phase Ib/II||Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM||SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer||Completed||USA||0|